Tech Company Financing Transactions

Selecta Biosciences Funding Round

On 10/15/2014, Selecta Biosciences secured $20 million in funding from private investors.

Transaction Overview

Announced On
10/15/2014
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Undisclosed
Investors
Proceeds Purpose
With strong financial support from both our current and new investors, we are now well positioned to rapidly advance our immune tolerance pipeline, including the lead program SEL-212, the first non-immunogenic treatment for refractory and tophaceous gout.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
480 Arsenal St.
Watertown, MA 02472
USA
Email Address
Overview
Selecta Biosciences, Inc. (NASDAQ: SELB) is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.
Profile
Selecta Biosciences LinkedIn Company Profile
Social Media
Selecta Biosciences Company Twitter Account
Company News
Selecta Biosciences News
Facebook
Selecta Biosciences on Facebook
YouTube
Selecta Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Werner Cautreels
  Werner Cautreels LinkedIn Profile  Werner Cautreels Twitter Account  Werner Cautreels News  Werner Cautreels on Facebook
Chief Financial Officer
John Leaman
  John Leaman LinkedIn Profile  John Leaman Twitter Account  John Leaman News  John Leaman on Facebook
Chief Medical Officer
Earl Sands
  Earl Sands LinkedIn Profile  Earl Sands Twitter Account  Earl Sands News  Earl Sands on Facebook
Chief Operating Officer
Lloyd Johnston
  Lloyd Johnston LinkedIn Profile  Lloyd Johnston Twitter Account  Lloyd Johnston News  Lloyd Johnston on Facebook
Chief Scientific Officer
Takashi Kishimoto
  Takashi Kishimoto LinkedIn Profile  Takashi Kishimoto Twitter Account  Takashi Kishimoto News  Takashi Kishimoto on Facebook
VP - Bus. Development
Stephen Smolinski
  Stephen Smolinski LinkedIn Profile  Stephen Smolinski Twitter Account  Stephen Smolinski News  Stephen Smolinski on Facebook
VP - General Counsel
David Abraham
  David Abraham LinkedIn Profile  David Abraham Twitter Account  David Abraham News  David Abraham on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/15/2014: Qstream venture capital transaction
Next: 10/15/2014: RadPad venture capital transaction

 

Share this article

 


About Our VC Transactions Data

Our team works diligently to report on all VC transactions involving tech companies. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary